Kornimate/medical-research-clean huggingface dataset:
role of lung ultrasound in screening for interstitial lung disease in patients with rheumatoid arthritis

Conditions: Interstitial Lung Disease; Rheumatoid Arthritis

Summary: the aim of this observational cross-sectional study is to assess accuracy of lung ultrasound to early diagnose ild among rheumatoid arthritis patients. rheumatoid arthritis patients with suggestive history of chest troubles will be evaluated using chest ultrasound and high resolution ct chest to evaluate ability of chest ultrasound to early diagnose ild among rheumatoid arthritis patients.

interstitial lung disease (ild) is a common complication of connective tissue disease (ctd) and a leading cause of morbidity and mortality. thus, early diagnosis and treatment may improve the prognosis of patients with ild. high-resolution computed tomography (hrct) is the gold standard for ild diagnosis. it can detect the location and type of lesions through its high resolution. unfortunately, it is hampered by high cost and potential risks associated with radiation exposure, especially for pregnant women. accordingly, finding a low-cost, non-invasive, and non-ionizing diagnostic method is necessary for ild. lung ultrasound (lus) has all of these advantages and is an accessible bedside procedure. as a result, it is easily accepted by patients. over the last 20 years, lus has mainly been applied in ctd-ild diagnosis, where it has shown high sensitivity and specificity. the assessment of ild by lus is determined by the number of b-lines, which appear as a comet tail signal and originate from the pleural line without fading to the edge of the screen. the total number of b-lines was found to correlate well with the hrct score. to assess the number of b-lines, previous studies used various scoring systems by designing different intercostal spaces (lis), such as 72 lis, 50 lis, and 14 lis. this study aims to assess lung ultrasound as a screening tool for early interstitial lung disease in connective tissue disease patients.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of rheumatoid arthritis and suspicion of interstitial lung disease on history and/ or clinical examination, age \> 18 years exclusion criteria: * patients who refuse to participate in the study, * patients with a history of pulmonary neoplasia or * patients with causes of interstitial fluid, such as, heart failure, diastolic dysfunction, asthma or pulmonary edema.
comparison between ticl and icl+ak for high myopic astigmatism

Conditions: Astigmatism; High Myopia

Summary: to compare the outcomes of a toric implantable collamer lens (icl) and a spherical implantable collamer lens combined with astigmatic keratotomy (ak) in the correction of high myopic astigmatism.


Eligibility criteria:
inclusion criteria: * age ranged from 18 to 40 years, * myopia greater than -8.00 diopters (d), and refractive cylinder in the range of 1.50d to 5.50d, * for the patients who were planned to undergo ak+icl implantation, the axial difference between the corneal astigmatism and the manifest refractive astigmatism was less than 10 degree, * a stable refractive error during the previous 2 years, * anterior chamber depth more than 2.8 mm, * endothelial cell density (ecd) more than 2500 cells/mm2, and * scotopic pupillary diameter less than 7 mm. exclusion criteria: * subjects had significant irregular astigmatism, corneal pathological changes, glaucoma, ocular inflammation, or previous ocular trauma or surgery.

Keywords: astigmatism high myopia phakic intraocular lens astigmatic keratotomy toric
time to intubation (tti) of obese patients. a comparison macintosh laryngoscope and stortz video laryngoscope

Conditions: Obese

Summary: the purpose of the study is to investigate wether the use of the stortz video laryngoscope will render in shorter time for the intubation of obese patients compared with the use of a conventional macintosh laryngoscope.

obese patients are prone to develop desaturation soon after initiation of anaesthesia compared to patients of normal body weight. it is therefore important to keep the time from when spontaneous breathing to when the airway is secured with a orotracheal tube as short as possible. we will therefore investigate if it is possible to shorten this time by using a stortz videolaryngoscope. patients 18-60 years with asa grade 1-3 and bmi \< 35 that turn up for planned surgery that demands the use of orotracheal tubing and controlled ventilation will be randomly and consecutively enrolled in either of two groups. patients in both groups will be anaesthetised with the same combination of drugs using propofol and remifentanyl or fentanyl for induction of sleep, combined with rocuronium for muscle relaxation. after the induction and relaxation the intubation will be facilitated using either of two laryngoscopes. in the first group a conventional macintosh laryngoscope, and in the second group a stortz videolaryngoscope will be used. the time to intubation is defined as the time from grabbing the laryngoscope to when the tube has been inserted and end-tidal carbon dioxide appears on the monitor. our hypothesis is that we will be able to achieve a faster intubation with the use of videolaryngoscope.

Eligibility criteria:
inclusion criteria: * age 18-60 * obesity defined as bmi \> 35 * asa 1-3 exclusion criteria: -known or suspected difficult airway
dynamic 99mtc-tetrofosmin czt-spect myocardial perfusion imaging in comparison with fractional flow reserve in patients after acute coronary syndrome

Conditions: Myocardial Infarction

Summary: dynamic 99mtc-tetrofosmin czt-spect myocardial perfusion imaging (mpi) is an advanced functional imaging technique giving important myocardial flow quantification added data in comparison with conventional mpi, especially in coronary multi vessel disease. a large-scale validation of diagnostic performances of myocardial flow reserve (mfr) estimated with dynamic 99mtc-tetrofosmin czt-spect mpi would allow a non-invasive approach instead of invasive intra-coronary fractional flow reserve (ffr) measurement. the aim of this prospective study is to assess diagnostic performances of mfr calculated with dynamic 99mtc-tetrofosmin czt-spect mpi in comparison with invasive intra-coronary ffr measurement in patients with significant residual coronary arteries stenosis after acute coronary syndrome .


Eligibility criteria:
inclusion criteria: * adult patient. * multi vessel coronary arteries disease (at least one non-culprit coronary stenosis \&gt;= 50%) diagnosis during * primary percutaneous coronary intervention \&lt; 12h after st-elevation myocardial infarction opercutaneous revascularisation of the culprit lesion within 24 to 48 hours of an acute non-st-segment elevation coronary syndrome. * written consent. * social security affiliation exclusion criteria: * non adult patient. * adult patient under tutelage. * reproductive age women. * medical history of myocardial infarction or coronary artery bypass surgery. * cardiogenic shock. * cardiomyopathy. * regadenoson/adenosine/ffr contraindication. * 99mtc-tetrofosmin hypersensibility. * small non-culprit coronary arteries. * participation to another interventional study.

Keywords: dynamic 99mtc-tetrofosmin czt-spect myocardial perfusion imaging fractional flow reserve acute coronary syndrome
neuro-navigated tms for chronic sci patients

Conditions: Spinal Cord Injuries

Summary: can neuro-navigated transcranial magnetic stimulation be used as an additional outcome measure to em-sci assessments in a spinal cord injury trial? * compare em-sci assessment with ntms in ten chronic thoracic sci patients * compare em-sci assessment with ntms in ten chronic cervical sci patients

this is an exciting time for translating experimental advanced therapies into treatments for spinal cord injury (sci). there are currently no regenerative therapies available that target the underlying biology. over the last 5 years the investigating team have developed a viable gene therapy approach for treating sci in pre-clinical models. the investigators are on the cusp of translating this therapy to first-in-human studies and are leading a programme to establish a world-first regenerative gene therapy for traumatic sci affecting upper limb mobility (since recovery of arm/hand function is one of the highest patient priorities). the team will develop an innovative trial design involving neurosurgical delivery of the gene therapy into the spinal cord, followed by specialist neurorehabilitation. for a clinical trial to have the best chance of success, one of the key steps needed to be addressed include validation of new assessment methods for the clinical trial. our aim is to determine whether neuro-navigated transcranial magnetic stimulation (ntms) can be used as an adjunct to standard assessments of function in sci patients. following two patient and public involvement events (patient focus group and feedback for project design with our rehabilitation partners), the investigating team will recruit chronic sci subjects to carry out european multicenter study about sci (em-sci) assessments. em-sci assessments are well established assessment tools for sci patients and include the em-sci 'core' assessments (isncsci, wisci-iii, walk test, scim 3) and em-sci 'additional' assessments (grassp, pain score, neurophysiology). following this investigators will compare and validate ntms with em-sci assessments in stable chronic sci patients with both cervical and thoracic injuries. ntms with combined tractography mri of the cortico-spinal tract (the main motor pathway of the spinal cord) will allow functional characterisation and density measurements of this tract in sci patients.

Eligibility criteria:
inclusion criteria: * single traumatic event at least 6 months prior to recruitment * isncsci grade a, b, c or d * able to participate in em-sci and ntms assessments and capable of informed consent exclusion criteria: * history of malignancy * history of other neurological disease * pregnancy * other cord lesions or tethering * cord transaction or penetrating injury
safety and pk study of bibf 1120 in japanese patients with ipf: follow up study from 1199.31(nct01136174)

Conditions: Pulmonary Fibrosis

Summary: primary objective of this study is to investigate the long-term tolerability and safety profile of bibf 1120 on top of pirfenidone treatment in patients with idiopathic pulmonary fibrosis who have completed a prior clinical trial of bibf 1120 (1199.31). secondary objectives are to assess effects on some efficacy criteria during long term treatment with bibf 1120 on top of pirfenidone.


Eligibility criteria:
inclusion criteria: 1. written informed consent consistent with good clinical practice (gcp) signed prior to entry into the study 2. completion of 1199.31 study and still under treatment with pirfenidone at a stable dose exclusion criteria: 1. any disease that may interfere with testing procedures or in judgement of investigator may interfere with trial participation or may put the patient at risk when participating in this trial. reconsider carefully all exclusion criteria of trial 1199.31. however, patients may qualify for participation even though they meet the exclusion criteria (for 1199.31), if the investigators benefit-risk assessment remains favorable. 2. any other investigational therapy received within 8 weeks before visit 1. 3. for female: pregnant women or women who are breast feeding or of child bearing potential not using a highly effective method of birth control for both at least 4 weeks prior to enrolment and 10 weeks after last study drug intake. for male: sexually active males not committing to using condoms both during the course of the study and ten weeks after last study drug intake (except if their partner is not of childbearing potential). 4. known or suspected active alcohol or drug abuse. 5. patients who require full-dose therapeutic anticoagulation (e.g. vitamin k antagonists, heparin), except low dose heparin and/or heparin flash as needed for maintenance of an indwelling intravenous device. as an example, prophylactic use of heparin, e.g. enoxaparin 2000 international unit (i.u.) subcutaneously (s.c.) per day, should be allowed. 6. patients who require full-dose antiplatelet (e.g. acetyl salicylic acid, clopidogrel) therapy. as an example, chronic low-dose acetyl salicylic acid, below or equal to 100 mg per day, should be allowed. 7. patient not compliant in previous trial, with trial medication or trial visits.
muscle-targeted nutritional therapy for the recovery from covid-19

Conditions: Sarcopenia

Summary: to assess the impact of a muscle-targeted nutritional therapy consisting of nutritional counseling and high-quality whey protein-based oral nutritional supplements enriched with leucine and vitamin d, on the recovery of post-covid-19 patients


Eligibility criteria:
inclusion criteria: * sarcopenia (revised european working group on sarcopenia in older people criteria) * recent discharge from hospital for covid-19 * informed consent exclusion criteria: * any malignant disease during the last five years * known kidney failure (previous glomerular filtration rate \<30 ml/min); * known liver failure (child b or c) * psychiatric disease * endocrine disorders associated with disorders of calcium metabolism (excluding osteoporosis) * indications related to the study product: more than 10 µg (400 iu) of daily vitamin d intake from medical sources. more than 500 mg of daily calcium intake from medical sources. adherence to a high energy or high protein diet up or use of protein containing or amino acid containing nutritional supplements up to three months before starting the study. * known allergy to milk, milk products or other components of the proposed interventions * indication to or ongoing artificial nutrition support * inclusion in other nutrition intervention trials * investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements * refusal
pilot study using oral capsule fmt to decolonize gi cre

Conditions: Enterobacteriaceae Infections; Fecal Microbiota Transplantation

Summary: carbapenem-resistant enterobacteriaceae (cre) are bacteria that have become resistant to carbapenems by producing enzymes that break down carbapenems. the prevalence of cre continues to rise globally but the treatment options are extremely limited. in case series, isolation of cre from any site, whether there is clinical infection or not, has been associated with all-cause hospital mortality ranging from 29% to 52%. there are no known methods for reliably decolonizing gastrointestinal (gi) cre. in rare case reports, fecal microbiota transplant (fmt) has successfully eradicated gastrointestinal colonization of cre, but there has been no larger study further investigating this. fmt via oral capsules is the least invasive method and has demonstrated efficacy and short-term safety in treating patients with recurrent clostridium difficile infections. therefore, the investigators propose this pilot study to determine the effectiveness of oral capsule fecal transplantation in the decolonization of gastrointestinal cre.


Eligibility criteria:
inclusion criteria: * outpatient * have intestinal carriage of cre exclusion criteria: * pregnant * peripheral wbc \>12 x 10\^9/l and/or temperature \>38 degrees celsius * swallowing dysfunction or known chronic aspiration * delayed gastric emptying * history of intestinal obstruction * active cre infection * acute exacerbation of underlying comorbid condition * severely immunocompromised patients * inflammatory bowel disease * allergies to ingredients generally recognized as safe * adverse event attributable to previous fmt * concomitant antibiotic use or antibiotic use 48 hours before fmt

Keywords: cre
to evaluate the efficacy and safety of dw1903 in acute and chronic gastritis patient

Conditions: Gastritis Acute; Gastritis Chronic

Summary: a multi-center, double-blind, randomized, parallel, active-controlled, non-inferiority, phase iii clinical trial to evaluate the efficacy and safety of dw1903 in patients with gastritis


Eligibility criteria:
inclusion criteria: * patients who were diagnosed with acute or chronic gastritis in a gastroscopy performed within 7 days prior to administration of this trial. * at least one or more erosions have been identified on gastroscopy. * patients who decided to voluntarily participate in this trial and agreed in writing. exclusion criteria: * patients who can not undergo gastroscopy * peptic ulcer (except scarring) and reflux esophagitis * patients who have had gastric acid suppression surgery or stomach/esophagus surgery (except for simple perforation surgery and appendectomy) * patients with a history of gastrointestinal malignancies * zollinger-ellison syndrome patients * patient with spontaneous coagulation disorder * patients with an allergic or hypersensitive response to a study drug * patients with a potential pregnancy. * patients who had clinically significant abnormalities in the screening test. * pregnant and lactating women * those currently taking other study drugs * patients who were judged to be ineligible for the trial by the principle investigator and the person in charge.
neuromuscular responses to recovery techniques

Conditions: Muscle Soreness

Summary: cold water immersion (cwi) and percussive massage therapy (pmt) are commonly used re-covery techniques in team sports. in particular, despite its wide use, pmt has been scarcely investigated in the literature, especially regarding neuromuscular measures and in comparison with other techniques. this study aims to evaluate and compare the acute and short-term ef-fects (24 h) of cwi and pmt on muscle strength, contractile properties, and soreness after exercise. a randomized crossover study will be performed on sixteen male soccer players (22 y, 20-27) who participate in three experimental sessions involving high-intensity training and 12-min recovery including cwi (10 °c water), bilateral pmt on the anterior and posterior thigh, or passive resting. outcomes will be assessed immediately after the exercise protocol, after the recovery intervention, and at 24 h. isometric knee extension (ike) and flexion (ikf), and tensiomyography (tmg) will be assessed.muscle soreness and fatigue will be scored from 0 to 10.

participants will be invited to participate to a cross-over randomized trial, consisting in 3 experimental sessions at 7 days of distance one from another. during each experimental session, participants will be asked to train for about 45 min at a high-intensity protocol (high-intensity intermittent running, plyometric jumps and isometric chair position). after the exercise, participants will be assessed for neuromuscular function (isometric strength and tensiomyography) as well as perceived soreness and fatigue. then, in a randomized order, participants will receive three different recovery interventions: cold water immersion, percussive massage, or a passive control condition. after the recovery intervention, outcomes are assessed again, as well as at 24 h. isometric strength is assessed with a dynamometer during knee extension and knee flexion. tensiomyography is performed on the thigh muscles, and time to contraction and radial displacement are considered as outcomes. soreness and fatigue are rated by the participant from 0 to 10.

Eligibility criteria:
inclusion criteria: * being healthy * training in soccer for more than 3 years and with a training frequency \> 2 times/week exclusion criteria: * reported time-loss injuries * using analgesics or other therapies affecting muscle function or pain

Keywords: recovery team sport cryotherapy massage guns
the basket study of pyrotinib maleate for her2-postive solid tumor

Conditions: Solid Tumor; HER2 Gene Mutation; HER-2 Gene Amplification; HER-2 Protein Overexpression

Summary: this is an open-label, phase 2 study exploring the efficacy and safety of 马来酸pyrotinib maleate tablets in patients with solid tumors with activating（harmful） her2 mutations or with her2 gene amplification or immunohistochemical staining (ihc) assay showing her2 is 3+ and / or fluorescence in situ hybridization (fish) positive.


Eligibility criteria:
inclusion criteria 1. patients between the ages of 18 and 75; 2. ecog physical status score 0-2 points; 3. the estimated total survival period is not less than 12 weeks; 4. patients with her2-positive solid tumors confirmed by pathology and identified as advanced tumors by clinicians or centers; 5. her2 positive: refers to standard immunohistochemical staining (ihc) assay showing her2 is 3+ and / or fluorescence in situ hybridization (fish) positive or after second generation sequencing shows her2 amplification and copy number ≥ 3, or there is a her2 activating mutation identified by the molecular oncology committee (confirmed by the investigator at the test center) ; 6. imaging studies have at least one measurable lesion with a diameter ≥ 10 mm; 7. pilotinib has not been used for the past 3 months; 8. the main organs function normally, they meet the following criteria: 1. blood routine examination criteria are to comply with: ①.hb≥100 g/l; ②.anc ≥ 1.5 × 109 / l; ③.plt≥75×109 /l; 2. biochemical tests are subject to the following criteria ①.tbil ≤ 1.5 × uln (upper limit of normal value); ②.alt and ast ≤ 2.5 × uln; if there is liver metastasis, alt and ast ≤ 5 × uln; ③.serum creatinine ≤ 1.5 × uln, creatinine clearance ≥ 50ml / min (based on cockroft and gault formula); 3. heart color ultrasound: left ventricular ejection fraction (lvef) ≥ 50%; 9. the patient or his legal guardian understands the test procedure and content and signs an informed consent form (icf) to provide true and effective information in accordance with the research and follow-up procedures; exclusion criteria: 1. there is a third interstitial fluid that cannot be controlled by drainage or other methods, such as pleural effusion and ascites; 2. it has many factors affecting the oral and absorption of drugs (such as inability to swallow, postoperative gastrointestinal resection, chronic diarrhea and intestinal obstruction); 3. those who have been confirmed to be allergic to the drug components of this program; 4. patients who are known to be pregnant or planning to become pregnant, or gestational age patients who are unwilling to take effective contraceptive measures throughout the trial; 5. patients with severe concomitant diseases or those considered by the investigator to be unsuitable for inclusion. 6. the investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of the study (for administrative reasons or for other reasons).